Ginkgo Bioworks is a synthetic biology company that builds and operates automated laboratory infrastructure for programming cells, serving customers in pharmaceuticals, agriculture, industrial biotechnology and food. Its offerings are organized around Cloud Lab, Datapoints and Solutions, which give partners access to Ginkgo's automated foundry, biological datasets and end-to-end R&D programs. Founded in 2008 by MIT scientists Jason Kelly, Reshma Shetty, Barry Canton, Tom Knight and Austin Che, Ginkgo went public via SPAC merger in September 2021 and trades on the NYSE as DNA. It divested its Biosecurity segment in April 2026, retaining roughly 20% of the acquirer.
Ginkgo Bioworks is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Employees
201–500
Total Funding
$789M
7 rounds
Last Private Valuation
$4B
Sep 19, 2019
Divested Biosecurity segment to Tower Biosecurity, keeping ~20% equity stake to refocus on core cell engineering.
Portfolio narrows to core cell-engineering; retains minority upside in a now-private biosecurity spinout.
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $789M across 7 rounds
Last updated 09-20-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 28, 2020 | Series E Extension (Illumina) Press release | $70M | — | Illumina |
| Sep 19, 2019 | Series E Press release | $290M | $4B | T. Rowe Price Associates |
| Dec 14, 2017 | Series D | $275M | — | General Atlantic |
Jason Kelly
Co-Founder, Chief Executive Officer and Director
Reshma Shetty
Co-Founder, President and Director
Steven Coen
Chief Financial Officer
Barry Canton
Co-Founder and Chief Technology Officer
Jennifer Wipf
Chief Commercial Officer; assumed day-to-day operating responsibilities from the Chief Operating Officer role effective January 1, 2026
Ginkgo Bioworks completed a SPAC merger with Soaring Eagle Capital Partners and began trading on the New York Stock Exchange under ticker DNA on September 17, 2021. The company raised $2.5 billion in gross proceeds, including $775 million in PIPE funding and approximately $858 million from the SPAC trust account.
Ginkgo Bioworks shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Ginkgo Bioworks had a valuation of approximately $4B at the time of its public offering. Current market capitalization fluctuates with the share price.
Ginkgo Bioworks raised $789M across 7 disclosed funding rounds prior to its public listing.
Ginkgo Bioworks was co-founded by Jason Kelly, Reshma Shetty, and Barry Canton in 2008.
Ginkgo Bioworks is headquartered in Boston, MA, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.